The Path to FDA Approval: When to Consider a Pre-IND Meeting



The road to FDA approval requires a blend of scientific precision, regulatory finesse, and strategic foresight. Early collaboration with the FDA isn't just advisable—it's essential. This strategic partnership allows companies to fine-tune their development strategies, ensuring alignment with regulatory standards and anticipating potential hurdles. At the heart of this journey lies the Pre-Investigational New Drug (Pre-IND) meeting—an invaluable chance for companies to gain early insight from FDA and solidify their path before stepping into clinical trials.

In this blog post, we'll walk through the steps of securing and navigating a Pre-IND meeting. Understanding when and how to engage with the FDA at this critical point can significantly impact the success of your drug development efforts.

Significance of Pre-IND Meetings

Pre-IND meetings serve as vital forums for life science companies to interact with the FDA, offering a platform to discuss development plans and seek regulatory guidance. These meetings provide clarity on regulatory requirements, helping companies navigate complex landscapes with confidence. Early engagement fosters collaboration between industry stakeholders and regulatory authorities, laying the groundwork for successful FDA approval.

Early Meeting Processes

Setting the tone for productive interactions begins with careful planning of which questions to include in the Meeting Request and ensuring that the right supporting data is included in the Meeting Package. Preparation involves compiling documentation and addressing potential questions proactively. Engaging with FDA reviewers early in a development program fosters open communication and collaboration, laying a strong foundation for successful IND filing.

Pre-IND Preparation

As life science digital marketers, we all know that content and SEO go hand-in-hand. But crafting content that resonates with your audience isn’t just about keyword research. It’s about the application of those keywords into dynamic content. Content serves as the bridge connecting researchers, clinicians, and industry professionals, offering insights, solutions, and innovations that shape the future of the field. It’s also what will help your offering stand above the competition.

Preparing for a Pre-IND meeting requires meticulous planning, including:

  • Gathering relevant data,
  • Compiling comprehensive materials
  • Anticipating regulatory concerns, and
  • Developing the right questions to guide each company’s unique development plan.

Pre-IND meetings are considered a Type B Milestone meeting. When planning for a Pre-IND meeting, companies must ensure that they align with the appropriate timelines. Pre-IND meetings are scheduled 60 days after the FDA receives the Meeting Request. Meeting Packages must be submitted to FDA no later than before the scheduled date of the meeting.

After a Pre-IND Meeting

Post-meeting follow-up is essential, addressing action items and incorporating feedback from the FDA into your development plan is necessary to progress effectively. Companies should be sure to document any commitments made to the FDA during the Pre-IND meeting to ensure that they are met as the development plan progresses.

If there are any lingering questions for the FDA after a Pre-IND, a company may want to pursue a formal “Follow-up” opportunity with the agency. To ensure the sponsor’s understanding of FDA feedback from meeting discussions, companies may submit clarifying questions to the Agency. This request for clarification must be submitted 20 days following the receipt of meeting minutes and is only intended to clarify FDA comments, rather than to raise new issues or proposals.

In Review

In conclusion, Pre-IND meetings are vital in the FDA approval process for life science companies. Proactively engaging with the FDA and seeking regulatory guidance early on enables companies to navigate drug development complexities effectively. We encourage all life science professionals to recognize the importance of Pre-IND meetings and embrace the collaborative nature of regulatory interactions.

Are you beginning the process of meeting with the FDA? Bracken is here to help. We developed a calculator to provide you with a clearer understanding of the timing and steps required to get an FDA meeting granted on the timeline that fits your program, as well as a robust checklist to keep you on track.

Contact us today to learn about collaborating with Bracken’s regulatory team.

Subscribe to receive more content